Rye Brook, N.Y., October 18, 2021 – LLS mourns the passing of Colin Powell. His death is a reminder of the seriousness of the pandemic and the ongoing need to protect the most vulnerable in our society.Read More
(New York, NY - Sept. 28, 2021) — The Able Channel, the world’s first streaming digital health platform delivering inspiration, information, and innovation for families meeting the challenges of disability & lifelong health concerns, has announced The Leukemia & Lymphoma Society (LLS) as its first foundational partner. Read More
FDA Approves New Treatment Option for Common and Serious Complication of Life-saving Stem Cell TransplantsPosted On: September 24, 2021
Rye Brook, N.Y., September 24, 2021 — The U.S. Read More
Rye Brook, N.Y., September 21, 2021 – A diverse group of cancer experts from leading academic institutions (UCLA, Emory University, NYU, Stanford University), the National Cancer Institute, and The Leukemia & Lymphoma Society (LLS) published recommendations for maximizing protection against COVID-19 among patients with blood cancer. The paper was published online in Blood Cancer Discovery, a journal of the American Association for Cancer Research.Read More
Rye Brook, N.Y., September 17, 2021 - The U.S. Read More
Rye Brook, N.Y., Sept. 17, 2021—The Leukemia & Lymphoma Society thanks members of the House Energy & Commerce Committee and the House Ways & Means Committee who voted to take critical steps to reduce barriers to care and increase affordability for many of the nearly 1.5 million people in the U.S. living with blood cancer. These crucial reforms will ensure more people can get the treatment they need at the moment they need it.Read More
Rye Brook, N.Y., September 14, 2021 - The U.S. Food and Drug Administration (FDA) recently approved zanubrutinib (Brukinsa®) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). This is the second therapy approved specifically for the treatment of this rare type of lymphoma. Zanubrutinib is a next-generation BTK inhibitor, which is designed to provide more targeted treatment with improved tolerability.
(Rye Brook, NY, Sept. 10, 2021) — Our top priority is — and always has been — the safety of blood cancer patients and survivors. We know that they are at increased risk of serious illness and death from COVID-19. However, up to 1 in 4 blood cancer patients won’t produce COVID-19 antibodies after vaccination, making it even more important for those around them to be vaccinated.Read More
Please send all media-related inquiries and interview requests to firstname.lastname@example.org. An LLS representative will respond as soon as possible.